Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Who benefits from medical interventions?

Literature DB >> 8298415

Who benefits from medical interventions?

G D Smith, M Egger.

Abstract

Mesh：

Substances：

Year: 1994 PMID： 8298415 PMCID： PMC2539180 DOI： 10.1136/bmj.308.6921.72

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

17 in total

1. An assessment of clinically useful measures of the consequences of treatment.

Authors: A Laupacis; D L Sackett; R S Roberts
Journal: N Engl J Med Date: 1988-06-30 Impact factor: 91.245

2. Attacks on heart diseases.

Authors: R Horton
Journal: Lancet Date: 1993-11-20 Impact factor: 79.321

3. Sounding board. Risks of correcting the risks of coronary disease and stroke with drugs.

Authors: M F Oliver
Journal: N Engl J Med Date: 1982-02-04 Impact factor: 91.245

Review 4. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit.

Authors: M H Alderman
Journal: Ann Intern Med Date: 1993-08-15 Impact factor: 25.391

5. Management of raised blood pressure in New Zealand: a discussion document.

Authors: R Jackson; P Barham; J Bills; T Birch; L McLennan; S MacMahon; T Maling
Journal: BMJ Date: 1993-07-10

6. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.

Authors: E Z Oddone; P Cowper; J D Hamilton; D B Matchar; P Hartigan; G Samsa; M Simberkoff; J R Feussner
Journal: BMJ Date: 1993-11-20

7. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors: M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245

8. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors: M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal: Ann Intern Med Date: 1990-05-15 Impact factor: 25.391

Review 9. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors: R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal: Lancet Date: 1990-04-07 Impact factor: 79.321

10. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.

Authors: T C Merigan; D A Amato; J Balsley; M Power; W A Price; S Benoit; A Perez-Michael; A Brownstein; A S Kramer; D Brettler
Journal: Blood Date: 1991-08-15 Impact factor: 22.113

29 in total

1. Tackling health inequalities in primary care. Exploring possible solutions to a problem is more important than describing the problem.

Authors: J Macleod; R Loudon
Journal: BMJ Date: 1999-08-14

2. Disease impact number and population impact number: population perspectives to measures of risk and benefit.

Authors: R F Heller; A J Dobson
Journal: BMJ Date: 2000-10-14

Review 3. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

Authors: J A Sterne; M Egger; G D Smith
Journal: BMJ Date: 2001-07-14

Who benefits from medical interventions?

1. An assessment of clinically useful measures of the consequences of treatment.

2. Attacks on heart diseases.

3. Sounding board. Risks of correcting the risks of coronary disease and stroke with drugs.

Review 4. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit.

5. Management of raised blood pressure in New Zealand: a discussion document.

6. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.

7. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

8. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Review 9. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

10. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.

1. Tackling health inequalities in primary care. Exploring possible solutions to a problem is more important than describing the problem.

2. Disease impact number and population impact number: population perspectives to measures of risk and benefit.

Review 3. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

4. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

5. Knowledge of cardiothoracic ratio adds to cardiovascular risk stratification.

Review 6. The relation between treatment benefit and underlying risk in meta-analysis.

Review 7. Getting research findings into practice. When to act on the evidence.

8. Cigarette smoking in British men and selection for coronary artery bypass surgery.

9. Coronary artery bypass surgery in smokers.

Review 10. Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits.